Open AccessSurvival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer
Author(s) -
Francis I. Macedo,
Emily L. Ryon,
Shishir K. Maithel,
Rachel Lee,
David A. Kooby,
Ryan C. Fields,
William G. Hawkins,
Gregory M. Williams,
Ugwuji N. Maduekwe,
Hong Joo Kim,
Syed A. Ahmad,
Sameer H. Patel,
Daniel E. Abbott,
Patrick B. Schwartz,
Sharon M. Weber,
Charles R. Scoggins,
Robert Martin,
Vikas Dudeja,
Dido Franceschi,
Alan S. Livingstone,
Nipun B. Merchant
Publication year - 2019
Publication title -
annals of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.153
H-Index - 309
eISSN - 1528-1140
pISSN - 0003-4932
DOI - 10.1097/sla.0000000000003468
Subject(s) - medicine , folfirinox , gemcitabine , oncology , chemotherapy , pancreatic cancer , paclitaxel , nab paclitaxel , neoadjuvant therapy , pathological , cancer , irinotecan , breast cancer , colorectal cancer
To compare the survival outcomes associated with clinical and pathological response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant chemotherapy (NAC) with FOLFIRINOX (FLX) or gemcitabine/nab-paclitaxel (GNP) followed by curative-intent pancreatectomy.